Home » Stocks » MDWD

MediWound Ltd. (MDWD)

Stock Price: $3.68 USD 0.01 (0.27%)
Updated December 3, 4:00 PM EST - Market closed

MDWD Stock Price Chart

Key Info

Market Cap 100.14M
Revenue (ttm) 31.79M
Net Income (ttm) 4.96M
Shares Out 27.18M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $3.68
Previous Close $3.67
Change ($) 0.01
Change (%) 0.27%
Day's Open 3.70
Day's Range 3.64 - 3.82
Day's Volume 34,485
52-Week Range 1.46 - 4.14

MDWD Stock News

GlobeNewsWire - 1 month ago

Bromelain Degradation of Biofilms Could Provide Clinically Meaningful Benefits in Wound Healing Bromelain Degradation of Biofilms Could Provide Clinically Meaningful Benefits in Wound Healing

GlobeNewsWire - 2 months ago

YAVNE, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet...

Seeking Alpha - 2 months ago

MediWound: An Underfollowed Opportunity At A Discount

GlobeNewsWire - 3 months ago

YAVNE, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet n...

GlobeNewsWire - 3 months ago

YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that th...

Other stocks mentioned: VCEL
Seeking Alpha - 3 months ago

Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and -15.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

Submitted Biological License Application to the FDA for NexoBrid  EscharEx U.S. Phase 2 Study Resumed Patient Screening

Zacks Investment Research - 4 months ago

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe bu...

Zacks Investment Research - 4 months ago

MediWound (MDWD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

YAVNE, Israel, June 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in s...

Seeking Alpha - 6 months ago

Mediwound, An Attractive Opportunity Through The Coronavirus Crisis

Zacks Investment Research - 6 months ago

Investors always look for companies with a high level of profitability regardless of the present market condition.

Other stocks mentioned: BWXT, ISDR, TNK
Seeking Alpha - 6 months ago

MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

MediWound (MDWD) delivered earnings and revenue surprises of 35.71% and 4.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 6 months ago

Shares of MediWound (NASDAQ:MDWD) moved higher by 6% in pre-market trading after the company reported Q1 results.

GlobeNewsWire - 6 months ago

EscharEx U.S. Phase 2 Study Resumed Patient Screening EscharEx U.S. Phase 2 Study Resumed Patient Screening

Zacks Investment Research - 6 months ago

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 6 months ago

YAVNE, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in se...

GlobeNewsWire - 7 months ago

Company Announces Appointments of Samuel Moed and David Fox Chairman Stephen T. Wills Named Executive Chairman Company Announces Appointments of Samuel Moed and David Fox Chairman Stephen T. W...

GlobeNewsWire - 8 months ago

YAVNE, Israel, March 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet n...

GlobeNewsWire - 9 months ago

Total non-dilutive funds for NexoBrid now valued at over $200 million Total non-dilutive funds for NexoBrid now valued at over $200 million

Seeking Alpha - 9 months ago

Mediwound Ltd (MDWD) CEO Sharon Malka on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

MediWound (MDWD) delivered earnings and revenue surprises of -8.33% and 32.86%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 10 months ago

YAVNE, Israel, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe bu...

GlobeNewsWire - 10 months ago

YAVNE, Israel and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that th...

GlobeNewsWire - 11 months ago

YAVNE, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe bu...

GlobeNewsWire - 1 year ago

Interim assessment anticipated by end of 2020 Interim assessment anticipated by end of 2020

Seeking Alpha - 1 year ago

MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

MediWound (MDWD) delivered earnings and revenue surprises of 15.38% and 92.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

YAVNE, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe b...

Seeking Alpha - 1 year ago

MediWound Ltd. (MDWD) CEO Sharon Malka on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

MediWound (MDWD) delivered earnings and revenue surprises of 20.00% and 194.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

MediWound Ltd.'s (MDWD) CEO Sharon Malka on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

MediWound (MDWD) delivered earnings and revenue surprises of -7.14% and -23.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

MediWound (MDWD) CEO, Gal Cohen on Q4 2018 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About MDWD

MediWound, an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase ... [Read more...]

Industry
Biotechnology
IPO Date
Mar 20, 2014
CEO
Sharon Malka
Employees
74
Stock Exchange
NASDAQ
Ticker Symbol
MDWD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for MediWound stock is "Strong Buy." The 12-month stock price forecast is 6.50, which is an increase of 76.63% from the latest price.

Price Target
$6.50
(76.63% upside)
Analyst Consensus: Strong Buy